Editors’ note: Have you read our 13-page special report on the 340B Coalition Winter Conference? We’ve received excellent feedback and think you and your colleagues will find it beneficial. Let us know what you think. Write to us at
Category: Regulatory
Drug manufacturers are doing a better job of providing the Health Resources and Services Administration (HRSA) with timely and accurate data needed to verify their 340B ceiling prices, the head of the federal 340B drug pricing program indicated today. Nonetheless,
…The Trump administration today asked Congress again to require 340B covered entities to report their 340B program savings and uses to the Health Resources and Services Administration (HRSA).
The administration made the request in its proposed federal budget for fiscal
…CMS Takes Another Step Toward Collecting Hospitals’ 340B Acquisition Costs
The Centers for Medicare & Medicaid Services (CMS) has taken another step toward requiring hospitals to let it see their 340B drug acquisition costs so CMS can base the hospitals’
…President Expected to Address Drug Prices in State of the Union Message
In his State of the Union address tonight, President Trump is expected to announce an initiative to make insulin more affordable and to challenge Congress to pass legislation
…CMS Unveils Medicaid Block Grant Option, Ramifications for 340B Unclear
The Centers for Medicare & Medicaid Services (CMS) this morning invited state Medicaid directors to pilot test giving up open-ended federal Medicaid funding for able-bodied adults in exchange for a
…Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law”
Hospital group 340B Health yesterday swung back hard against a congressional watchdog agency’s recommendations for stricter federal policing of 340B duplicate discounts, calling them “misguided, unworkable, and contrary
…BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts
The U.S. Department of Health and Human Services (HHS) lacks “reasonable assurance” that states and healthcare providers are complying with the prohibition against subjecting drug manufacturers to payment of duplicate 340B discounts
…(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share
…